Contributor Page
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Email  |  Website  |  Articles
Contact Details
Tel: +1 202 4084000
Fax: +1 202 4084400
901 New York Avenue, NW
Washington, DC
United States
By Samuel V. Eichner, Margaret Esquenet
On October 26, 2018, the Library of Congress adopted exemptions to the prohibitions in 17 U.S.C. § 1201(a)(1)(A), which prohibits circumvention of technological measures that control access to copyrighted works.
By Adriana Burgy, Stacey Lewis, Thomas Irving
The Federal Circuit issued decisions in Novartis AG v. Ezra Ventures LLC, -- F.3d __, 2018 WL 6423564 (CHEN, Moore, Stoll) and Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical...
By John Paul, Brian Kacedon, Cecilia Sanabria
The damages expert for a patent infringer claimed that a 0% royalty was proper based on the existence of a non-infringing alternative that had not yet hit the market.
By John Paul, Brian Kacedon, Cecilia Sanabria, Alexander Poonai
The Eleventh Circuit found the amount of damages resulting from fraud and breach of an asset purchase agreement should be assessed at the time the agreement was negotiated
By Benjamin T. Hemmelgarn, Adriana Burgy
Three prominent IP groups propose amending § 101 to clarify what is patentable subject matter. The American Bar Association (ABA) IP Section, and the Intellectual Property Owners Association (IPO)
By Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Prosecution Pointer 153.
By J. Michael Jakes
Suppose you apply for a patent and the U.S. Patent and Trademark Office rejects your application.
By Safiya Aguilar, M. Andrew Holtman
On November 26, 2018, FDA published an outline of the numerous improvements to the 510(k) program.
By Clara N. Jiménez, Margaret Esquenet
As the 2018 playoffs neared, Boston Celtics' fans were worried because star point guard Kyrie Irving was injured and unable to play.
By Kate Leonard
Advanced Marketing Systems (AMS) appeals the Final Written Decisions in four CBM proceedings where the PTAB found that the challenged patents were eligible for CBM review and subsequently held that the challenged claims are unpatentable.
By Daniel Klodowski, David Seastrunk, Michael R Galgano, Aaron Parker, Elliot C. Cook
Finnegan's PTAB stats team is pleased to supplement our standard monthly statistics with a new look at how claims have fared over time for IPR cases reaching final written decision.
By Jessica Marks, Virginia Carron
Lab-engineered meats, milks, gelatin and other replacements for animal-based foods is a growing industry.
By Ryan McDonnell
In Hamilton Beach Brands, Inc. v. f'real Foods, LLC, 2018-1274, the Federal Circuit affirmed the PTAB's patentability determination based on a construction adopted for the first time in the
By Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
The USPTO business centers that participate in the e-Office Action program include.
By Matthew Luneack
Assignor estoppel is an equitable defense that prevents an assignor of a patent from later challenging the patent's validity.
Contributor's Topics